FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893985849> ?p ?o ?g. }

• W2893985849 endingPage "6851" @default.
• W2893985849 startingPage "6838" @default.
• W2893985849 abstract "Abstract Chemoradiation therapy is the mainstay for treatment of locally advanced, borderline resectable pancreatic cancer. Pharmacologic ascorbate (P-AscH−, i.e., intravenous infusions of ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations capable of selective cytotoxicity to tumor cells. In doses achievable in humans, P-AscH− decreases the viability and proliferative capacity of pancreatic cancer via a hydrogen peroxide (H2O2)-mediated mechanism. In this study, we demonstrate that P-AscH− radiosensitizes pancreatic cancer cells but inhibits radiation-induced damage to normal cells. Specifically, radiation-induced decreases in clonogenic survival and double-stranded DNA breaks in tumor cells, but not in normal cells, were enhanced by P-AscH−, while radiation-induced intestinal damage, collagen deposition, and oxidative stress were also reduced with P-AscH− in normal tissue. We also report on our first-in-human phase I trial that infused P-AscH− during the radiotherapy “beam on.” Specifically, treatment with P-AscH− increased median overall survival compared with our institutional average (21.7 vs. 12.7 months, P = 0.08) and the E4201 trial (21.7 vs. 11.1 months). Progression-free survival in P-AscH−–treated subjects was also greater than our institutional average (13.7 vs. 4.6 months, P &lt; 0.05) and the E4201 trial (6.0 months). Results indicated that P-AscH− in combination with gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma is safe and well tolerated with suggestions of efficacy. Because of the potential effect size and minimal toxicity, our findings suggest that investigation of P-AscH− efficacy is warranted in a phase II clinical trial. Significance: These findings demonstrate that pharmacologic ascorbate enhances pancreatic tumor cell radiation cytotoxicity in addition to offering potential protection from radiation damage in normal surrounding tissue, making it an optimal agent for improving treatment of locally advanced pancreatic adenocarcinoma." @default.
• W2893985849 created "2018-10-05" @default.
• W2893985849 creator A5009200111 @default.
• W2893985849 creator A5033569423 @default.
• W2893985849 creator A5040980527 @default.
• W2893985849 creator A5042309463 @default.
• W2893985849 creator A5044316011 @default.
• W2893985849 creator A5047906405 @default.
• W2893985849 creator A5055097161 @default.
• W2893985849 creator A5055806263 @default.
• W2893985849 creator A5061394495 @default.
• W2893985849 creator A5062515121 @default.
• W2893985849 creator A5073201452 @default.
• W2893985849 creator A5077897457 @default.
• W2893985849 creator A5082072789 @default.
• W2893985849 creator A5082497480 @default.
• W2893985849 creator A5084443904 @default.
• W2893985849 creator A5087974114 @default.
• W2893985849 date "2018-12-13" @default.
• W2893985849 modified "2023-10-14" @default.
• W2893985849 title "Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer" @default.
• W2893985849 cites W1972153352 @default.
• W2893985849 cites W1978407431 @default.
• W2893985849 cites W1982415526 @default.
• W2893985849 cites W1990035048 @default.
• W2893985849 cites W2007064404 @default.
• W2893985849 cites W2009760859 @default.
• W2893985849 cites W2011445960 @default.
• W2893985849 cites W2023533343 @default.
• W2893985849 cites W2043035748 @default.
• W2893985849 cites W2046608399 @default.
• W2893985849 cites W2054383376 @default.
• W2893985849 cites W2057725320 @default.
• W2893985849 cites W2071267404 @default.
• W2893985849 cites W2076098030 @default.
• W2893985849 cites W2083590898 @default.
• W2893985849 cites W2085134251 @default.
• W2893985849 cites W2090770691 @default.
• W2893985849 cites W2103711657 @default.
• W2893985849 cites W2106438648 @default.
• W2893985849 cites W2107603940 @default.
• W2893985849 cites W2112785574 @default.
• W2893985849 cites W2118519973 @default.
• W2893985849 cites W2118797060 @default.
• W2893985849 cites W2119370602 @default.
• W2893985849 cites W2139847043 @default.
• W2893985849 cites W2140035449 @default.
• W2893985849 cites W2140968862 @default.
• W2893985849 cites W2151253787 @default.
• W2893985849 cites W2152573554 @default.
• W2893985849 cites W2157653515 @default.
• W2893985849 cites W2165890143 @default.
• W2893985849 cites W2246750959 @default.
• W2893985849 cites W2294765885 @default.
• W2893985849 cites W2315255484 @default.
• W2893985849 cites W2346921980 @default.
• W2893985849 cites W2413386818 @default.
• W2893985849 cites W2523545996 @default.
• W2893985849 cites W2541436531 @default.
• W2893985849 cites W2577266312 @default.
• W2893985849 cites W2597494578 @default.
• W2893985849 cites W2781525129 @default.
• W2893985849 doi "https://doi.org/10.1158/0008-5472.can-18-1680" @default.
• W2893985849 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6295907" @default.
• W2893985849 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30254147" @default.
• W2893985849 hasPublicationYear "2018" @default.
• W2893985849 type Work @default.
• W2893985849 sameAs 2893985849 @default.
• W2893985849 citedByCount "69" @default.
• W2893985849 countsByYear W28939858492018 @default.
• W2893985849 countsByYear W28939858492019 @default.
• W2893985849 countsByYear W28939858492020 @default.
• W2893985849 countsByYear W28939858492021 @default.
• W2893985849 countsByYear W28939858492022 @default.
• W2893985849 countsByYear W28939858492023 @default.
• W2893985849 crossrefType "journal-article" @default.
• W2893985849 hasAuthorship W2893985849A5009200111 @default.
• W2893985849 hasAuthorship W2893985849A5033569423 @default.
• W2893985849 hasAuthorship W2893985849A5040980527 @default.
• W2893985849 hasAuthorship W2893985849A5042309463 @default.
• W2893985849 hasAuthorship W2893985849A5044316011 @default.
• W2893985849 hasAuthorship W2893985849A5047906405 @default.
• W2893985849 hasAuthorship W2893985849A5055097161 @default.
• W2893985849 hasAuthorship W2893985849A5055806263 @default.
• W2893985849 hasAuthorship W2893985849A5061394495 @default.
• W2893985849 hasAuthorship W2893985849A5062515121 @default.
• W2893985849 hasAuthorship W2893985849A5073201452 @default.
• W2893985849 hasAuthorship W2893985849A5077897457 @default.
• W2893985849 hasAuthorship W2893985849A5082072789 @default.
• W2893985849 hasAuthorship W2893985849A5082497480 @default.
• W2893985849 hasAuthorship W2893985849A5084443904 @default.
• W2893985849 hasAuthorship W2893985849A5087974114 @default.
• W2893985849 hasBestOaLocation W28939858491 @default.
• W2893985849 hasConcept C117262875 @default.
• W2893985849 hasConcept C121608353 @default.
• W2893985849 hasConcept C126322002 @default.
• W2893985849 hasConcept C185592680 @default.
• W2893985849 hasConcept C190283241 @default.

• next